ARS Pharmaceuticals, Inc. - Common Stock (SPRY)

CUSIP: 82835W108

Q1 2026 13F Holders as of 31 Mar 2026

Holder snapshot 7 signals
Share change
+3,913,561
Put/Call ratio
29%
SEC-reported price per share
$8.03
Number of holders
200
Value change
+$10,864,887
Number of buys
92
Open additional details 1 more signal available
Number of sells
81
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
98,457,811

Security key

82835W108

Report period

Q1 2026

Institutions

200

Top holders

10

Ownership snapshot

Top reported holders of SPRY - ARS Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
Sarina Tanimoto
Comparable rows
3/15
Latest evidence
02 Jan 2026
13F 13D/G 3/4/5 Lead comparable stake: 11% 12 rows are not safely comparable across share classes. 13D/G row: RA CAPITAL MANAGEMENT, L.P. Showing 1-6 of 15 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 11%.

3 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership Top 3
RA CAPITAL MANAGEMENT, L.P. 11%
Rubric Capital Management LP 8.1%
James E. Flynn 7.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
RA CAPITAL MANAGEMENT, L.P.
13F 13D/G
Company
11%
Reported 13D/G · 29 Sep 2025
$126,530,382
10,860,977 shares
— 31 Dec 2025
Rubric Capital Management LP
13F 13D/G
Company
8.1%
Reported 13D/G · 31 Mar 2026
$72,230,000
6,200,000 shares
— 31 Dec 2025
James E. Flynn
3/4/5 13D/G
10%+ Owner · Deerfield Management Company, L.P.
7.8%
Reported 13D/G · 30 Jul 2025
$180,437,416
9,774,508 shares
— 27 Jun 2025
Sarina Tanimoto
3/4/5
CHIEF MEDICAL OFFICER, 10%+ Owner
—
mixed-class rows
$203,017,758
12,468,141 shares
mixed-class rows
— 02 Jan 2026
Richard E. Lowenthal
3/4/5
PRESIDENT AND CEO, Director, 10%+ Owner
—
mixed-class rows
$202,790,460
12,418,141 shares
mixed-class rows
— 02 Jan 2026
ORBIMED ADVISORS LLC
13F
Company
13F
—
denominator unverified
$96,561,142
8,288,510 shares
— 31 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
200
Shares
94,099,513
Rows available
200
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q1 2026 Across Filers

Q1 2026 holders
200
Q1 2026 holders
200
Holder diff
0
Investor Q1 2026 Shares Q1 2026 Shares Share Diff Share Chg % Q1 2026 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .